Therefore, inhibiting PME-1 by AMZ30, or inhibiting PME-1-controlled MAPKAPK2-RIPK1 signaling by MK2i or necrostatin-1, could potentially limit an increase in neural cell death caused by high oxidative stress levels in patients with PSP or AD. Here, MAPKAPK2 is linked to supranuclear palsy, progressive, 1.